William Blair Has Negative Estimate for IDXX Q1 Earnings

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Equities researchers at William Blair cut their Q1 2025 earnings per share (EPS) estimates for shares of IDEXX Laboratories in a research note issued to investors on Monday, February 3rd. William Blair analyst R. Daniels now forecasts that the company will post earnings of $2.91 per share for the quarter, down from their previous forecast of $2.97. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $10.45 per share. William Blair also issued estimates for IDEXX Laboratories’ Q3 2025 earnings at $3.03 EPS, Q4 2025 earnings at $2.84 EPS and FY2025 earnings at $11.92 EPS.

Several other equities research analysts have also recently issued reports on the company. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Piper Sandler restated a “neutral” rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Bank of America boosted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday. Morgan Stanley decreased their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Finally, Leerink Partners initiated coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $524.38.

IDEXX Laboratories Trading Down 0.9 %

Shares of IDXX opened at $465.03 on Tuesday. The firm has a 50-day moving average price of $424.92 and a 200 day moving average price of $453.54. IDEXX Laboratories has a 12-month low of $398.50 and a 12-month high of $583.39. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $38.08 billion, a P/E ratio of 44.84, a P/E/G ratio of 3.64 and a beta of 1.37.

Insider Transactions at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.18% of the company’s stock.

Institutional Investors Weigh In On IDEXX Laboratories

A number of institutional investors have recently bought and sold shares of the stock. FSA Wealth Management LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $31,000. Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in shares of IDEXX Laboratories during the third quarter valued at $37,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.